KQ Labs, a programme delivered by the Francis Crick Institute and funded by LifeArc, is proud to announce its first exit as Glamorous AI, a company that was part of KQ Labs’ third cohort, has been acquired by X-Chem, the US based global leader in DNA-encoded library (DEL) driven discovery solutions.
Glamorous AI is a leader in artificial intelligence (AI) solutions for drug discovery. GlamorousAI is radically changing how drugs are designed and optimised using their proprietary artificial intelligence platform, RosalindAI, and applying it to low and sparse data problems inherent to drug discovery.
X-Chem is the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery and the first to demonstrate applying machine learning to large, high quality, DEL datasets can accelerate hit generation. The acquisition of the innovative AI capabilities of Glamorous AI positions X-Chem as a leading service provider in machine learning-driven drug discovery.
Noor Shaker, CEO and Founder of Glamorous AI said: “Glamorous AI is one of a few fortunate startups to have been accepted to the KQ labs programme. The programme provided a great opportunity to be part of an innovative ecosystem and connect with likeminded founders looking to transform the life sciences industry. With its focus on healthcare and life sciences, the programme has helped us build and strengthen our connections with the industry.”
Barbara Domayne-Hayman, who leads the KQ Labs programme, commented: “We are very excited that Glamorous AI has achieved this excellent result, and in such a short space of time. The greater resources that X-Chem can bring will enable wider uptake of Glamorous AI’s platform technology. We wish the Glamorous AI team every success in their next phase as they transition to the X-Chem organisation”.
Financial details were not disclosed.
Media contact
Hannah Severyn
Head of Media and PR at LifeArc
